title: Duration of psychosis and outcome in first-episode schizophrenia.
abstract: OBJECTIVE
  This study was undertaken to assess the potential effect of duration of untreated illness on outcome in a group of first-episode schizophrenic patients.
  
  
  METHODS
  Seventy patients with schizophrenia diagnosed according to the Research Diagnostic Criteria entered the study and were followed for up to 3 years. All patients received standardized treatment and uniform assessments both during the acute phase of their illness and throughout the follow-up period. Outcome was measured in terms of time to remission of acute psychotic symptoms as well as degree of symptom remission.
  
  
  RESULTS
  The mean duration of psychotic symptoms before initial treatment was 52 weeks, preceded by a substantial prepsychotic period. According to survival analysis, duration of illness before treatment was found to be significantly associated with time to remission as well as with level of remission. The effect of duration of illness on outcome remained significant when diagnosis and gender variables, themselves associated with outcome, were controlled in a regression analysis. Duration of illness was not correlated with age at onset, mode of onset, premorbid adjustment, or severity of illness at entry into the study.
  
  
  CONCLUSIONS
  Duration of psychosis before treatment may be an important predictor of outcome in first-episode schizophrenia. Acute psychotic symptoms could reflect an active morbid process which, if not ameliorated by neuroleptic drug treatment, may result in lasting morbidity. Further implications of these findings are discussed.
authors.affiliation: Research Department, Long Island Jewish-Hillside Medical Center, Glen Oaks 11004.
authors.forename: A D
authors.initials: AD
authors.lastname: Loebel
authors.forename: J A
authors.initials: JA
authors.lastname: Lieberman
authors.forename: J M
authors.initials: JM
authors.lastname: Alvir
authors.forename: D I
authors.initials: DI
authors.lastname: Mayerhoff
authors.forename: S H
authors.initials: SH
authors.lastname: Geisler
authors.forename: S R
authors.initials: SR
authors.lastname: Szymanski
mesh_terms: D000328:Adult; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D011569:Psychiatric Status Rating Scales; D011618:Psychotic Disorders / Q000175:diagnosis / Q000188:drug therapy / Q000523:psychology; D011619:Psychotropic Drugs / Q000627:therapeutic use; D012559:Schizophrenia / Q000175:diagnosis* / Q000188:drug therapy; D012565:Schizophrenic Psychology; D012720:Severity of Illness Index; D016019:Survival Analysis; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D011619:Psychotropic Drugs